A rumor regarding Crispr Therapeutics (CRSP) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of Crispr are up $1.14, or 2%, to $53.67 in morning trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- Cathie Wood Sells Tesla (TSLA) and SoFi Stocks, Makes a $34M Bet on This USDC Giant
- Crispr Therapeutics price target lowered to $77 from $87 at Citi
- Promising Outlook for Crispr Therapeutics AG: Buy Rating Backed by Strong Product Launches and Strategic Developments
- CRISPR Therapeutics Reports Q3 2025 Financial Results